Xeris Biopharma Holdings Inc. (NASDAQ:XERS)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
XERS Weekly Chart

Old Forum Content for XERS

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $XERS good news for this one. And it's commercial stage with a few approved and marketed drugs. Worth a look on a pullback. https://finance.yahoo.com/news/xeris-xers-licensing-deal-amgen-133000124.html
  • joelsg1: @woodman $XERS A 'Rev Shark' fave at The Street.
  • woodman: @joelsg1 $XERS - Thanks. (I'm not familiar with Rev Shark.)
  • mopick: $XERS, small cap biotech that has developed a drug deliery system that allows the medication to be easily delivered by an auto-injection. The Gvoke Hypopen is a glucagon injection used for a very low blood ugar. The company is working withother companies, such as Merk for various other applicatiolns. $3.00 is solid reistance, where it is now.
  • steve71: $MCRB Not for the fainthearted. I will be out before the close on Weds. Money good so far. $VRTX Biotechs go up and down. Vertex goes up. (There, I've jinxed it.) $XERS Their drug delivery platform is working. Now they just onboard more and more drugs.
  • woodman: @steve71 $MCRB $VRTX $XERS - Nice work with $MCRB.I never got on board though looked at it a lot. $$ tied up elsewhere so I never really got in gear with it. I think your idea to sell before PDUFA is a good one. Seems that approval is very likely, but the stock still isn't moving as hard as one would hope/expect. I get a $CDTX vibe with it (though MCRB does have much greater institutional support than CDTX did/does). I also think there are some questions about rollout post-approval.
  • steve71: @steve71 $MCRB $VRTX $XERS Guess I can only reply to myself, As an only child that's not a problem. I have also seen the JPM concern about slow early sales. That doesn't make sense to me. 20,000 C. diff deaths in U.S. yearly. C. diff is hard to treat initially. Recurrent C. diff is even more difficult, maybe because of drug resistance from the first round. So if recurrence can be 90% prevented why wouldn't the ICU doc treat every single initial case with SER-109? My bet is that every single primary case gets treatment - a run rate of 150,000 to 200,000 yearly in the U.S. alone. So I am hoping for post approval weakness for another bite of the apple.
  • woodman: @steve71 $MCRB $VRTX $XERS - Makes sense. Often the post-approval dips turn out to be great opportunities. CDTX is still suffering from its post-approval migraine. (No position in CDTX currently.)
  • JosephM: $XERS..picked up a smidge of this spec at $4.50...5 days to cover this pos.
  • JosephM: $XERS...shorts covering...hey there's lunch $.
  • Mikev200: $XERS day 2, yesterday vol 2.5 avg.
  • stelllamaris: @Mikev200 $XERS being pumped on twitter ...some guy named William Mead...not sure if he's legit or not...but it moved large after his tweet
  • efrain007: @stelllamaris $XERS I follow him and he seems legit.... I think. A lot of the squeezes he mentions work out. $BBIG is another he just mentioned saying that going near $5 might trigger a squeeze because open interest is bullish.... though I know nothing about options.
  • Mikev200: @stelllamaris $XERS Thanks GTK.
  • Mikev200: $XERS big move on volume, holding above 50sma
  • mopick: $XERS, nh, in from below
  • mopick: $XERS, started a position in this pharma company specializing in drug delivery, ready-to-use injectable drug system. Avoids the need for refrigeration for drugs like insulin. Their 'Evoke Hypo-Pen injection of glucagon for severe hypoglycemic for people with diabetes is their main drug.
Visit the Trading Forum to join in the discussion.
Stock Price $1.78
Change 2.30%
Volume 1,319,000

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations.

Request Video of XERS
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!